PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 498
- Registration Number
- NCT01244061
- Locations
- 🇺🇸
Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, California, United States
🇦🇺Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇨🇦Canadian Phase Onward Inc., Toronto, Ontario, Canada
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
- Conditions
- HypercholesterolemiaDyslipidemia
- Interventions
- Biological: PF-04950615 (RN316)
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 68
- Registration Number
- NCT01243151
- Locations
- 🇺🇸
Vince and Associates Clinical Research, Overland Park, Kansas, United States
🇺🇸Healthcare Discoveries, LLC dba ICON Development Solutions, San Antonio, Texas, United States
🇺🇸SeaView Research, Inc., Miami, Florida, United States
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1101
- Registration Number
- NCT01241591
- Locations
- 🇦🇹
Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhuegel, Wien, Austria
🇧🇪Cliniques universitaires Saint-Luc, Bruxelles, Belgium
🇧🇦Department for skin and venerial diseases, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 105
- Registration Number
- NCT01240915
- Locations
- 🇺🇸
Metropolitan Gastroenterology Group, PC - Chevy Chase Clinical Research, Chevy Chase, Maryland, United States
🇸🇰Gastroenterologicke a hepatologicke oddelenie, V. interna klinika LFUK a UN Bratislava, Ruzinov, Bratislava, Slovakia
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2012-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT01239745
- Locations
- 🇭🇷
University Hospital Center Osijek, Osijek, Croatia
🇭🇷University Hospital Center Split, Split, Croatia
🇪🇪North Estonia Medical Centre Foundation, Tallinn, Estonia
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: ACC-001
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT01238991
- Locations
- 🇯🇵
Shonan Atsugi Hospital, Atsugi, Kanagawa, Japan
🇯🇵Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, Japan
🇯🇵Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT01237327
- Locations
- 🇨🇳
The 2nd Central Hospital of Tianjin, Tianjin, China
🇨🇳Cancer Hospital, Shanghai, China
🇨🇳The 1st Affiliated Hospital, Xi'an Jiao Tong University, Xi'an, China
Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2012-03-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT01236378
- Locations
- 🇨🇳
Pfizer Investigational Site, Shanghai, China
A Study Evaluating the Absorption Of Varenicline Through The Skin Following Once Daily Application Of A Patch For 14 Days
- Conditions
- Smoking Cessation
- Interventions
- Drug: placebo patch
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2011-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT01234142
- Locations
- 🇺🇸
Pfizer Investigational Site, Fargo, North Dakota, United States
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 172
- Registration Number
- NCT01233869
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸Southwest Kidney Institute, PLC, Tempe, Arizona, United States
🇺🇸Capital Nephrology Clinical Research, Sacramento, California, United States